Meta-iodobenzylguanidine (mIBG) was initially developed as a scintigraphic agent to allow imaging of the adrenal medulla (Wieland et al., 1980) . The concept of targeted radionuclide therapy for neuroblastoma with '311-mIBG follows naturally from its successful use in the diagnosis and staging of phaeochromocytoma, neuroblastoma and other tumours of neural crest origin (Hoefnagel et al., 1987) . As the uptake of mIBG by neuroblastoma varies considerably from one patient to another (Moyes et al., 1989) , targeted radiotherapy by itself seems unlikely to be an adequate treatment, yet it is apparent from the considerable experience which has accrued from its use in children with relapsed or refractory neuroblastoma, that it is a valuable addition to the therapeutic armamentarium (Lewis et al., 1991 , Vofite et al., 1991 . The most appropriate combination and optimal scheduling of mIBG with chemotherapy, external beam radiotherapy and surgery has yet to be determined.
In most circumstances, smaller volumes of tumour are more easily eradicated than larger masses by both radiotherapy and chemotherapy. The reasons for this are complex. While it is principally due to the greater number of clonogenic cells in larger tumours, poorer penetration of drugs and the presence of hypoxic cells may also make larger tumours more resistant to the effects of chemotherapy and radiotherapy respectively. The decreasing probability of cure with a given radiation dose in increasingly large tumours has been calculated, taking into account the number of clonogenic cells, but not considering any protective effect due to hypoxia .
In the case of targeted radiotherapy, other factors are pertinent. These include the penetration of the radiopharmaceutical, the proportion of tumour cells which are targeted, the intracellular localisation of the targeting agent, the retention of the radiopharmaceutical, the half-life of the conjugated radionuclide, and the physical properties of the emitted radiation. This radiation may be characterised in terms of its type, whether alpha and beta particles, gamma rays or Auger electrons, and in terms of its path length. It is the path length which is of greatest relevance when considering the likely effect on micrometastases of different sizes.
In targeted radiotherapy with mIBG it has been suggested that smaller tumours might be more difficult to eradicate if the conjugated radionuclide is "'lI, at least within the microtumour size range up to about 1 mm, and assuming uniform distribution of the radionuclide . The explanation for this paradoxthat smaller neuroblastoma tumours might be more difficult to cure with '311-mIBG -lies in the physical characteristics of the radiation emitted by '3'I (Humm, 1986) . As the mean path length of its beta particles is 800 gLm, virtually all the beta particle energy released by the disintegration of '"'I evenly spread throughout a spherical tumour is absorbed within that tumour if its diameter is greater than 20 mm and a progressively smaller fraction is absorbed if its diameter is less. The calculated fraction of absorbed energy, 0, for tumours between 200 ym and 1000 ttm is shown in Figure 1 . In tumours larger than about 1 mm, the benefit of increased energy absorption is offset by increasing clonogenic cell number. The 'optimal tumour size' for 1311 therapy is calculated to be 1-2mm .
There is clearly a balance between these microdosimetric considerations which predict the relative resistance of smaller tumour deposits to targeted therapy, and the clonogenic cell number and other factors which make larger tumours more resistant. A mathematical model has been developed to consider the likely relative importance of these factors in determining the probability of cure of tumours of different sizes . This has predicted that the microdosimetric factor will be of greater importance in micrometastases, with the result that very small tumours will be less easy to cure. The aim of the present study was to test the prediction that very small tumours are relatively resistant to '1g-mIBG therapy.
Multicellular spheroids of human neuroblastoma cells have been shown to be a useful in vitro model for the assessment of targeted radiotherapy with monoclonal antibodies (Walker et al., 1988) . The aim of the present study was to determine, using this model, whether the size of neuroblastoma micrometastases is an important factor in the efficacy of mIBG therapy, as predicted by microdosimetric calculations.
Materials and methods

Cell lines
The human neuroblastoma cell line used in this study was SK-N-BE(2c), although NB1-G (Carachi et al., 1987) was the line used in the original description of the spheroid model for the assessment of targeted therapy (Walker et al., 1988) . SK-N-BE(2c) was derived from the bone marrow of a patient with progressive neuroblastoma following treatment with radiotherapy and chemotherapy (Biedler et al., 1978 ). This cell line was chosen because it exhibits a greater degree of active uptake of mIBG Montaldo et al., 1991) than NBI-G (Mairs et al., 1991b Experimental treatment Experiments were carried out with both 'small' (approximately 250 tim diameter) and 'large' (approximately 400 jLm diameter) neuroblastoma spheroids. Each experiment was performed at least twice. Aliquots of spheroids were transferred to 25 ml sterile plastic screw-topped vessels ('universal containers') and allowed to settle. The supernatant was removed and replaced with fresh medium containing '3'ImIBG. The concentrations of '31I-mIBG used initially were 1.2, 2.4, 3.6 and 4.8 MBq ml'. In order to determine the '31I-mIBG concentration needed to cure more than 50% of small spheroids, a concentration of 6.0 MBq ml-' was used in addition. The spheroids and mIBG were then incubated for 2 h with intermittent agitation at 37'C. This incubation period was chosen because we have shown that accumulation of mIBG by neuroblastoma spheroids increases up to this time (Mairs et al., 1991a (Mairs et al., 1991a) . Following the incubation, the medium was removed and spheroids were rinsed twice in phosphate buffered saline to remove any unbound mIBG. Spheroids were then immediately transferred individually by micropipette into separate wells of a 24 well plate which had been base coated with 1.25% Noble agar and contained 0.5 ml supplemented medium. The plates were incubated at 37'C in 5% CO2, and 0.5 ml fresh medium was added to each well at weekly intervals.
Endpoints
The cross sectional area of each spheroid was measured on day zero and three times a week thereafter using a semiautomated image analysis system coupled via a television camera to an inverted optical microscope similar to that described by Twentyman (1982 Specific regrowth delay can only be calculated if more than half the spheroids regrow following treatment. Detailed analysis using Monte Carlo methods has shown that calculation of regrowth delay from the median value of observations in which up to 50% of spheroids are cured are valid (Wheldon & Brunton, 1982) . This is because the 'cured' spheroids are not lost to the analysis -even if assigned infinite growth delays they contribute to the identification of the median of the data set.
As an alternative endpoint the proportion of spheroids 'cured' by treatment was calculated. Spheroid 'cure' may be determined experimentally in different ways. In the outgrowth assay, spheroids are placed in regular tissue culture multiwells and observed for cellular outgrowth. Spheroids which fail to form any cellular outgrowth are deemed to be 'cured'. This assay requires surviving cells to form a colony and is therefore similar to clonogenic assay, but does not require disaggregation of the spheroid. Alternatively in the regrowth assay spheroids are placed individually in agar-coated wells to prevent adhesion to the base and measured regularly. Spheroids which fail to achieve a certain volume increase within a specified time are considered 'cured'. Although this definition is of necessity somewhat arbitrary, it has been used satisfactorily to define spheroid 'cure' by this group (e.g. Wheldon et al., 1985) and others (e.g. Schwachofer et al., 1989) . There is no evidence to suggest that the results obtained with the outgrowth assay differ materially from the regrowth assay. In this study we elected to use the regrowth assay as 'cure' rates may be determined on groups of spheroids being observed for regrowth delay, whereas the outgrowth assay would have required additional spheroids to have been plated and observed separately. In this paper spheroids were considered 'cured' if they failed to achieve a 5-fold volume increase in the duration of the experiment, usually 3 weeks.
The endpoints of regrowth delay and 'cure' were chosen as a good correlation has been shown between tumour spheroid radiosensitivity estimates derived from regrowth delay, cure and clonogenic assays (Pourreau-Schneider & Malaise, 1981; West et al., 1984; Moore et al., 1987) .
Controls
In each experiment, the growth of untreated spheroids was measured and compared with that of treated spheroids. To show that any effect on spheroid growth was due to 31I-mIBG, experiments were repeated using either non-radiolabelled mIBG (1 mM and 2 mM), or '3'I-sodium iodide (1.2, 2.4, 3.6, 4.8 and 6.0 MBq ml') in place of '31I-mIBG. In addition, the effect of 2, 4, 6, 8 and 1O Gy external beam irradiation from a 60 Co teletherapy source on SK-N-BE(2c) spheroids of different sizes was measured in the same way. Doses larger than 6 Gy 'cured' too many spheroids of both sizes to allow the specific regrowth delay to be calculated. To establish whether there is any interaction between the chemical, mIBG, and radiation, that is to see if mIBG acts as a radiosensitiser, the effect of external beam irradiation on spheroids incubated with non-radiolabelled mIBG was also determined.
Statistics
Confidence intervals for medians were calculated according to the method described by Campbell and Gardner (1989) . Proportions of small and large spheroids cured were compared by a modification of Fisher's exact test (Campbell & Machin, 1990) .
Results
A concentration related cytotoxic effect of '3'I-mIBG on SK-N-BE(2c) neuroblastoma spheroids was observed. Typical regrowth curves for 400 1sm diameter spheroids treated with 2.4, 3.6 and 4.8 MBq m'l 3I11-mIBG are shown in Figure 2 . Figure 3 shows the specific regrowth delay of small and large spheroids produced by '31I-mIBG. At a concentration of 1.2 MBq ml-' no difference was seen. At 2.4 MBq ml-' the data points overlap, but the spread of values for large spheroids suggests that the effect is greater than on small spheroids. At 3.6 MBq ml-' there is a clear difference in the specific regrowth delay between small and large spheroids, with the latter being more affected. In two experiments on large spheroids at this dose level the specific regrowth delay could not be calculated as too few spheroids regrew to permit the derivation of a Tio value. At 4.8 MBq ml-', the highest concentration tested against 400 jim diameter spheroids, too many were 'cured' to quantify specific regrowth delay. At 6.0 MBq ml-', the highest concentration tested against 250 jim diameter spheroids, too many were 'cured' to allow calculation of specific regrowth delay values. Figure 3 shows that an '3'I-mIBG concentration of only 3.6 MBq ml-' is required to produce a similar specific regrowth delay on 400 lim diameter spheroids as is produced by 4.8 MBq ml-' on 250 gm diameter spheroids. Figure 4 shows the proportion of small and large spheroids cured at each dose level used. The data from all experiments at each '3'I-mIBG concentration were pooled: the mean number of individual spheroids used to calculate the value for each point on this graph was 60. These results show that 4.8 MBq ml1' 'cures' a significantly greater proportion of large than small spheroids (Xc2 = 55.9, P <0.001). The dose required to cure 50% of spheroids (TCD50) was derived by 13"1-mlBG concentration (MBq ml-1) Spheroids treated with activities of '3'I-sc 6.0 MBq ml-' showed no regrowth dela: 'cured'. Similarly, no effect was seen on with non-radiolabelled mIBG up to concei which exceeds by a factor of four the ma tions of '3'I-mIBG used. In addition, the beam irradiation on spheroids incubatec labelled mIBG was indistinguishable fror external beam irradiation alone was used It is deduced that the toxicity demonstral the incorporation of radioactive mIBG by cells, as these control experiments have sh4 be attributed to the '3'I or the mIBG interaction between mIBG and radiation.
The specific regrowth delay produced irradiation on small and large SK-N-BI shown in Figure 5 . As a given dose prodi on spheroids of both sizes, it is deduced seen with the targeted radiotherapy is di characteristics of '31I.
Discussion
Although the sizes of spheroids chosen in and 400g1m, are relatively close together, ti difference in the absorbed fraction, 1, c about 20% for the smaller and 30% for ti (Figure 1) (Wheldon ilar absorbed radiet al., 1988 (Wheldon ilar absorbed radiet al., , 1991 ). An added benefit of this combined At 1.15 and 1.25, strategy is that it should encompass all tumour deposits and so reduce the importance of the problem of heterogeneity of uptake in tumour which may occur with targeted radiopharmaceuticals. This phenomenon, which has not been considered in the present analysis, will be of increasing importance with larger tumours, and may be a limiting factor experimental studies have shown that, in spheroids at least, uniform distribution of mIBG does occur in contrast to the marked heterogeneity seen with monoclonal antibodies (Mairs et al., 1991a) . The optimal scheduling of targeted radiotherapy with TBI has been investigated by O'Donoghue (1991) . A set of combined treatment schedules, chosen to be biologically equivalent to a TBI course of seven 2 Gy fractions are evaluated. The tumour effects of these schedules depend on the specificity of targeting, represented by the ratio of the initial dose rate for the tumour cells to that in the dose limiting normal organ, and the heterogeneity of targeting represented by the I selected patients has recently commenced.
In conclusion, this study produces data indicating that if targeted radiotherapy with '31I-mIBG is to be used successfully in patients with neuroblastoma, a means of overcoming the relative resistance of micrometastatic disease needs to be incorporated into the therapeutic strategy.
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